Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANCHOR-1 depemokimab in chronic rhinosinusitis with nasal polyps
NL-OMON56281Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Depemokimab + standard of care with Placebo + standard of care (2 arms). Primary endpoints: Change from baseline in total endoscopic nasal polyp score at Week 52 and Change from baseline in mean nasal obstruction score from Week 49 through Week 52. Started Dec 2022; status: completed.
02
Drugs
depemokimab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NL-OMON56281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56281.